Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The relationship between HMGCR genetic variation, alternative splicing, and statin efficacy.

Discovery medicine - 1 Jun 2010

Medina Marisa Wong

Abstract excerpt

Statins are a class of cholesterol lowering drugs that inhibit 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), the enzyme which catalyzes the rate limiting step of cholesterol biosynthesis. Although numerous trials have demonstrated statin efficacy in the reduction of cardiovascular dise...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alternative Splicing
Share to Exons
Share to HMGCR gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Variation

Share to Haplotypes

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Hydroxymethylglutaryl CoA Reductases

Share to Neoplasms

Source

Identifiers

PMID: 20587337

Genes

HMGCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20587337-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The relationship between HMGCR genetic variation, alternative splicing, and statin efficacy.PMID 20587337Read ↗

The role of HMGCR alternative splicing in statin efficacy.Semantic proximity Read ↗

Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin.Semantic proximity Read ↗

Pharmacogenomics of cholesterol-lowering therapy.Semantic proximity Read ↗

Genetic variation in 3-hydroxy-3-methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer.Semantic proximity Read ↗

HNRNPA1 regulates HMGCR alternative splicing and modulates cellular cholesterol metabolism.Semantic proximity Read ↗

Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment.Semantic proximity Read ↗

Pharmacogenetics of HMG-CoA Reductase Inhibitors: Optimizing the Prevention of Coronary Heart DiseaseSemantic proximity Read ↗

Common variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4, and CYP7A1 genes as predictors of lipid-lowering response to atorvastatin therapy.Semantic proximity Read ↗

Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon13.Semantic proximity Read ↗

Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease managementSemantic proximity Read ↗

A Mendelian Randomization Approach Using 3-HMG-Coenzyme-A Reductase Gene Variation to Evaluate the Association of Statin-Induced Low-Density Lipoprotein Cholesterol Lowering With Noncardiovascular Disease Phenotypes.Semantic proximity Read ↗

When the same treatment has different response: The role of pharmacogenomics in statin therapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.